Categories: NATURE

Reversing resistance to cancer immune therapy with antibodies that target GDF-15 protein


  • CLINICAL BRIEFINGS

The protein GDF-15 is a potent immunosuppressor that is overexpressed in many solid tumours and impedes the effects of cancer immunotherapy. In a first-in-human clinical trial, the GDF-15-targeting antibody visugromab reversed GDF-15-mediated resistance to immunotherapy, resulting in deep, long-lasting tumour regressions in some individuals.



Source link

fromermedia@gmail.com

Share
Published by
fromermedia@gmail.com

Recent Posts

Qualcomm wins a legal battle over Arm chip licensing

A federal jury in Delaware determined on Friday that Qualcomm didn’t breach its agreement with…

16 hours ago

Three Comic/Movie/Band Reviews | Cup of Jo

Geese The Wendy Award The Apprentice What have you read/watched/listened to lately? Phoebe Ward, 22,…

18 hours ago

Actually, Flipping Properties Can Improve Housing Affordability—Here’s How

15% ROI, 5% down loans!","body":"3.99% rate, 5% down! Access the BEST deals in the US…

18 hours ago

Is solar geoengineering research having its moment?

Particles in ship exhaust inadvertently cause cloud brightening – some geoengineering projects would try to…

18 hours ago

5 Great Games to Put You in the Winter Mood

The weather outside is frightful, but the iOS games are so delightful, let it play,…

18 hours ago

Banner year for fixed-income funds leaves TCW and Western Asset behind

A few flagship bond funds from some big-name Southern California-based firms saw outflows of more…

18 hours ago